{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.1","upperLimit":"71.7","value":"41.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"The TTF was defined as the time from the start of moxetumomab pasudotox administration to the date of the first of relapse, progressive disease, initiation of alternative anticancer therapy, or death due to disease or disease-related complication. The TTF was censored on the date of last disease assessment or hematologic assessment for participants who are alive with no documented relapse or PD prior to data cut-off, dropout, or the initiation of alternative anticancer therapy and also censored for death not accompanied by relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"MEDIAN","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Prior to each treatment cycle, EOT (up to 24 weeks), monthly from the EOT assessment until the Day 181 assessment (only for CBC), at follow-up visits every 3 months for the next 24 months, and every 6 months thereafter (approximately 6 years)","title":"Time to Treatment Failure (TTF) Assessed by Blinded Independent Central Review","type":"SECONDARY","unitOfMeasure":"Months"}